Analyst firms · Citigroup · ORIC
Citigroup ORIC price target and rating history
Oric Pharmaceuticals Inc. (ORIC) · Health Care
Citigroup rates Oric Pharmaceuticals Inc. (ORIC) Buy with a $10 price target, as of its latest action on Apr 4, 2022. It has published 3 rating actions on ORIC since July 2021, including 2 upgrades and 1 downgrade. Across 6 firms with a ORIC price target in the last 12 months, the median target is $23.50.
- Current rating
- Buy
- Price target
- $10
- Median target, all firms
- $23.50
- Actions on ORIC
- 3
Citigroup price target on ORIC
Every Citigroup rating on ORIC
- Apr 4, 2022
- Mar 22, 2022
- Jul 6, 2021
How other firms rate ORIC
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Outperform | $26 | Oct 5, 2026 |
| BTIG | Buy | $26 | Sep 23, 2026 |
| Stifel | Buy | $14 | Jun 12, 2026 |
| Goldman Sachs | Buy | $15 | May 15, 2026 |
| Piper Sandler | Overweight | $22 | Jan 7, 2026 |
| Evercore ISI | Outperform | $25 | Nov 20, 2025 |
| Wolfe Research | Peer Perform | Nov 18, 2025 |
Questions about Citigroup and ORIC
- What is Citigroup's price target for ORIC?
- Citigroup's latest stated price target for Oric Pharmaceuticals Inc. (ORIC) is $10, from its action on Apr 4, 2022.
- What is Citigroup's rating on ORIC?
- Citigroup rates ORIC Buy, a bullish rating, as of Apr 4, 2022.
- When did Citigroup last change its view on ORIC?
- On Apr 4, 2022, Citigroup upgrades to Buy from Neutral, price target $7 to $10.
- How does Citigroup's ORIC target compare with other analysts?
- Across 6 firms with a ORIC price target in the last 12 months, the median target is $23.50.
More ORIC rating histories
All Citigroup ratingsORIC news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.